{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-000474","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.638451+00:00","generated_at":"2026-06-05T02:24:40.588861+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vivani Medical appoints Daniel Bradbury to Board; former Amylin CEO led first once-weekly GLP-1 drug","bullets":["Daniel Bradbury appointed to board effective March 4, 2024, filling newly created vacancy expanding board from 5 to 6 members.","Bradbury was CEO of Amylin Pharmaceuticals until its $7.1B acquisition by Bristol-Myers Squibb in 2012; Amylin secured first once-weekly GLP-1 approval (Bydureon).","He will serve on Audit Committee; annual retainers: $35,000 for board, $10,000 for committee.","His GLP-1 expertise aligns with Vivani's lead programs: six-month GLP-1 implants NPM-115 (obesity) and NPM-119 (type 2 diabetes)."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-000474","json":"https://secwatch.observer/filing/0001753926-24-000474.json","markdown":"https://secwatch.observer/filing/0001753926-24-000474.md","text":"https://secwatch.observer/filing/0001753926-24-000474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624000474/0001753926-24-000474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624000474/g084105_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:24:40.588861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d7661aaee","claim":"Daniel Bradbury was appointed as Director at Vivani Medical, Inc..","evidence_excerpt":"unanimously appointed Daniel Bradbury to fill a newly created vacancy on the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624000474/0001753926-24-000474-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}